小鼠浆细胞瘤在体内的生长：白细胞介素6（IL-6）的促进作用以及抗IL-6或其受体抗体的抑制作用。
Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor.
作者信息
Vink A, Coulie P, Warnier G, Renauld J C, Stevens M, Donckers D, Van Snick J
机构信息
Ludwig Institute for Cancer Research, Brussels, Belgium.
出版信息
J Exp Med. 1990 Sep 1;172(3):997-1000. doi: 10.1084/jem.172.3.997.
Abstract
Murine plasmacytomas show a striking dependence on interleukin 6 (IL-6) for their growth in vitro. Here, we present evidence suggesting that IL-6 also plays an essential role in the in vivo development of these tumors. This conclusion is based on the finding that the tumorigenicity of an IL-6-dependent plasmacytoma cell line was increased approximately 100-fold on transfection with an IL-6 expression vector, whereas it was inhibited in animals treated with monoclonal antibodies capable of blocking the binding of IL-6 to its receptor. Injection of these antibodies 1 d before tumor challenge protected greater than 50% of the mice and retarded tumor growth in all animals. Tumors arising in antibody-treated mice retained their IL-6 dependence in vitro, suggesting that the level of protection could be improved if stronger IL-6 antagonists were available.
摘要
小鼠浆细胞瘤在体外生长时对白细胞介素6（IL-6）表现出显著依赖性。在此，我们提供证据表明IL-6在这些肿瘤的体内发生过程中也起着至关重要的作用。这一结论基于以下发现：用IL-6表达载体转染后，一株依赖IL-6的浆细胞瘤细胞系的致瘤性增加了约100倍，而在用能够阻断IL-6与其受体结合的单克隆抗体处理的动物中，致瘤性受到抑制。在肿瘤攻击前1天注射这些抗体可保护超过50%的小鼠，并延缓所有动物的肿瘤生长。在抗体处理的小鼠中产生的肿瘤在体外仍保持对IL-6的依赖性，这表明如果有更强的IL-6拮抗剂，保护水平可能会提高。
相似文献
1
Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor.小鼠浆细胞瘤在体内的生长：白细胞介素6（IL-6）的促进作用以及抗IL-6或其受体抗体的抑制作用。
J Exp Med. 1990 Sep 1;172(3):997-1000. doi: 10.1084/jem.172.3.997.
2
A monoclonal antibody specific for the murine IL-6-receptor inhibits the growth of a mouse plasmacytoma in vivo.
Curr Top Microbiol Immunol. 1990;166:43-6. doi: 10.1007/978-3-642-75889-8_6.
3
Interleukin 6 (IL-6) and its receptor (IL-6R) in myeloma/plasmacytoma.骨髓瘤/浆细胞瘤中的白细胞介素6（IL-6）及其受体（IL-6R）
Curr Top Microbiol Immunol. 1990;166:13-22. doi: 10.1007/978-3-642-75889-8_2.
4
Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models.在多种小鼠模型中，抗白细胞介素-6或其受体的单克隆抗体的作用揭示了白细胞介素-6在致死性脓毒性休克发病机制中的有限参与。
Eur J Immunol. 1992 Oct;22(10):2625-30. doi: 10.1002/eji.1830221023.
5
Interleukin-HP1, a T cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas.白细胞介素-HP1，一种由T细胞衍生的杂交瘤生长因子，可支持小鼠浆细胞瘤的体外生长。
J Exp Med. 1987 Mar 1;165(3):641-9. doi: 10.1084/jem.165.3.641.
6
Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130.抑瘤素M、白血病抑制因子和白细胞介素6通过共同信号转导子gp130诱导人浆细胞瘤细胞增殖。
J Exp Med. 1994 Apr 1;179(4):1343-7. doi: 10.1084/jem.179.4.1343.
7
Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody.
Cytokine. 1992 Jan;4(1):6-11. doi: 10.1016/1043-4666(92)90029-q.
8
Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.在白细胞介素-6缺陷的BALB/c小鼠中，降植烷油诱导的浆细胞瘤发育缺陷。
Am J Pathol. 1997 Sep;151(3):689-96.
9
Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice.白细胞介素（IL）-6/可溶性IL-6受体双转基因小鼠中的肝细胞增生、浆细胞瘤形成和髓外造血
Am J Pathol. 1998 Aug;153(2):639-48. doi: 10.1016/S0002-9440(10)65605-2.
10
引用本文的文献
1
Preclinical evaluation of topically-administered PEGylated Fab' lung toxicity.局部给药的聚乙二醇化Fab'肺毒性的临床前评估。
Int J Pharm X. 2019 Jun 21;1:100019. doi: 10.1016/j.ijpx.2019.100019. eCollection 2019 Dec.
2
IL-6 Promotes T Cell Proliferation and Expansion under Inflammatory Conditions in Association with Low-Level RORγt Expression.IL-6 促进炎症条件下 T 细胞的增殖和扩增，同时伴有低水平的 RORγt 表达。
J Immunol. 2018 Nov 15;201(10):2934-2946. doi: 10.4049/jimmunol.1800016. Epub 2018 Oct 12.
3
Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.白细胞介素6作为多发性骨髓瘤治疗靶点的临床前验证
Immunol Res. 2014 Aug;59(1-3):188-202. doi: 10.1007/s12026-014-8528-x.
4
IL-6 controls susceptibility to helminth infection by impeding Th2 responsiveness and altering the Treg phenotype in vivo.IL-6 通过抑制 Th2 反应和改变体内 Treg 表型来控制对寄生虫感染的易感性。
Eur J Immunol. 2014 Jan;44(1):150-61. doi: 10.1002/eji.201343746. Epub 2013 Nov 4.
5
Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models.华氏巨球蛋白血症：临床与免疫学方面、自然病史、起源细胞及新兴小鼠模型
ISRN Hematol. 2013 Sep 9;2013:815325. doi: 10.1155/2013/815325.
6
STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy.STAT3 活性对于小鼠免疫介导性心肌炎的发生是必需且充分的，并促进其向扩张型心肌病进展。
EMBO Mol Med. 2013 Apr;5(4):572-90. doi: 10.1002/emmm.201201876. Epub 2013 Mar 5.
7
IL-6 and MYC collaborate in plasma cell tumor formation in mice.白细胞介素-6 和 MYC 协同作用于小鼠浆细胞瘤的形成。
Blood. 2010 Mar 4;115(9):1746-54. doi: 10.1182/blood-2009-08-237941. Epub 2009 Dec 17.
8
Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity.血清白细胞介素-6、可溶性白细胞介素-6受体与克罗恩病活动度
Dig Dis Sci. 2008 Jan;53(1):242-7. doi: 10.1007/s10620-007-9849-6. Epub 2007 Jun 5.
9
New frontiers in the treatment of multiple myeloma.多发性骨髓瘤治疗的新前沿
ScientificWorldJournal. 2006 Dec 6;6:1475-503. doi: 10.1100/tsw.2006.236.
10
IL-6 transgenic mouse model for extraosseous plasmacytoma.用于骨外浆细胞瘤的白细胞介素-6转基因小鼠模型。
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1509-14. doi: 10.1073/pnas.022643999. Epub 2002 Jan 22.
本文引用的文献
1
Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants.用矿物油和矿物油佐剂在BALB/c品系小鼠中诱导浆细胞瘤。
Nature. 1962 Mar 17;193:1086-7. doi: 10.1038/1931086a0.
2
A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro.浆细胞瘤在体外生存和增殖所需的一种巨噬细胞衍生因子。
Science. 1986 Aug 1;233(4763):566-9. doi: 10.1126/science.3726549.
3
Interleukin-HP1, a T cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas.白细胞介素-HP1，一种由T细胞衍生的杂交瘤生长因子，可支持小鼠浆细胞瘤的体外生长。
J Exp Med. 1987 Mar 1;165(3):641-9. doi: 10.1084/jem.165.3.641.
4
The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells.B细胞刺激因子2（BSF-2/IL-6）在B细胞终末分化中的关键作用。
J Exp Med. 1988 Feb 1;167(2):332-44. doi: 10.1084/jem.167.2.332.
5
cDNA cloning of murine interleukin-HP1: homology with human interleukin 6.小鼠白细胞介素-HP1的cDNA克隆：与人白细胞介素6的同源性
Eur J Immunol. 1988 Feb;18(2):193-7. doi: 10.1002/eji.1830180202.
6
IgG1 plasmacytosis in interleukin 6 transgenic mice.白细胞介素6转基因小鼠中的IgG1浆细胞增多症。
Proc Natl Acad Sci U S A. 1989 Oct;86(19):7547-51. doi: 10.1073/pnas.86.19.7547.
7
Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma.白细胞介素3和白细胞介素6协同促进多发性骨髓瘤中恶性浆细胞前体的增殖和分化。
J Exp Med. 1989 Aug 1;170(2):613-8. doi: 10.1084/jem.170.2.613.
8
Establishment of two interleukin 6 (B cell stimulatory factor 2/interferon beta 2)-dependent human bone marrow-derived myeloma cell lines.两种依赖白细胞介素6（B细胞刺激因子2/干扰素β2）的人骨髓来源骨髓瘤细胞系的建立。
J Exp Med. 1989 Jan 1;169(1):339-44. doi: 10.1084/jem.169.1.339.
9
B cell growth and differentiation activity of interleukin-HP1 and related murine plasmacytoma growth factors. Synergy with interleukin 1.白细胞介素-HP1及相关小鼠浆细胞瘤生长因子的B细胞生长和分化活性。与白细胞介素1的协同作用。
Eur J Immunol. 1988 Apr;18(4):607-12. doi: 10.1002/eji.1830180418.
10
Growth autonomy and tumorigenicity of interleukin 6-dependent B cells transfected with interleukin 6 cDNA.用白细胞介素6 cDNA转染的白细胞介素6依赖性B细胞的生长自主性和致瘤性。
J Exp Med. 1990 Feb 1;171(2):389-400. doi: 10.1084/jem.171.2.389.
Zotero 插件